Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 12/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 11/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | GSK3B | P49841 | 2/20 | 0.68 |
| ▸ | MAOA | P21397 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | IGF1R | P08069 | 1/20 | 0.67 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.66 |
| ▸ | TTR | P02766 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545594 | 1.00 | PIM1 (1.00) | PIM1PIM2HPGDPIM3AKR1B1 | |
| SCHEMBL2547566 | 1.00 | PIM1 (1.00) | PIM1PIM2HPGDPIM3AKR1B1 | |
| SCHEMBL29195684 | 0.90 | PIM1 (0.81) | PIM1PIM2HPGDPIM3AKR1B1 | |
| SCHEMBL8167436 | 0.86 | PIM1 (0.75) | PIM1PIM2HPGDRAB9AMAOA | |
| SCHEMBL8167434 | 0.86 | PIM1 (0.75) | PIM1PIM2HPGDRAB9AMAOA | |
| SCHEMBL2539676 | 0.83 | PIM1 (1.00) | PIM1PIM2HPGDPIM3AKR1B1 | |
| SCHEMBL2539679 | 0.83 | PIM1 (1.00) | PIM1PIM2HPGDPIM3AKR1B1 | |
| SCHEMBL2539680 | 0.83 | PIM1 (1.00) | PIM1PIM2HPGDPIM3AKR1B1 | |
| SCHEMBL29195716 | 0.83 | PIM1 (0.68) | PIM1PIM2HPGDPIM3AKR1B1 | |
| SCHEMBL1299451 | 0.83 | HPGD (1.00) | PIM1PIM2HPGDMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | claimed |
| EP-2217235-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | Musc Foundation for Research Development (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009064486-A9 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2009-07-16 | — | — | WO | claimed |
| WO-2009064486-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-05-22 | — | — | WO | claimed |
| CN-118108785-A | 5 Alpha, 8 alpha-peroxy ergosterol-3-thiazolidinedione derivative, and preparation method and application thereof | 齐齐哈尔医学院 | 2024-05-31 | — | — | CN | disclosed |
| WO-2016115360-A1 | C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| US-8790855-B2 | Charge control agent and toner using same | HODOGAYA CHEMICAL CO., LTD (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2383263-B1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | UNIV CHOSUN IACF (KR) | 2014-04-16 | — | — | EP | disclosed |
| EP-2618218-A1 | CHARGE CONTROL AGENT AND TONER USING SAME | Hodogaya Chemical Co., Ltd. (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20130177843-A1 | CHARGE CONTROL AGENT AND TONER USING SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2217235-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | Musc Foundation for Research Development (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009064486-A9 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009064486-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2000018746-A1 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885HPGD 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.